“ac220” Archives

Entry Author Date Location
Ambit Biosciences Seeks $86M IPO as Market Warms Up 11/08/10 San Diego
Ambit, Buoyed by Astellas Deal, Attempting Rare Switch from Platform to Drug Developer 12/23/09 San Diego
Ambit Nabs Partnership With Astellas, $40M Upfront Cash, To Develop Leukemia Drug 12/18/09 San Diego
Ambit Biosciences, In Third Incarnation, Gears Up for Pivotal Study of Leukemia Drug 09/10/09 San Diego
Page 1 of 1